In reply 1

Affiliations

¹ BC Centre for Disease Control.
² Faculty of Medicine, University of British Columbia.
³ Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada email/email, Email: james.johnston@bccdc.ca.
⁴ BC Centre for Disease Control, Faculty of Medicine, University of British Columbia.

Comment

Lorena Mota et al. Int J Tuberc Lung Dis. 2016 Dec.

. 2016 Dec;20(12):1696.

doi: 10.5588/ijtld.16.0550-2.

¹ BC Centre for Disease Control.
² Faculty of Medicine, University of British Columbia.
³ Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada email/email, Email: james.johnston@bccdc.ca.
⁴ BC Centre for Disease Control, Faculty of Medicine, University of British Columbia.

No abstract available

Comment on

Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis.
Mota L, Al-Efraij K, Campbell JR, Cook VJ, Marra F, Johnston J. Mota L, et al. Int J Tuberc Lung Dis. 2016 Jun;20(6):819-26. doi: 10.5588/ijtld.15.0803. Int J Tuberc Lung Dis. 2016. PMID: 27155187
Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurements.
Sturkenboom MG, Bolhuis MS, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JC. Sturkenboom MG, et al. Int J Tuberc Lung Dis. 2016 Dec;20(12):1695-1696. doi: 10.5588/ijtld.16.0550. Int J Tuberc Lung Dis. 2016. PMID: 27931348 No abstract available.